viralytics ltd (VLA:ASX)
viralytics ltd (VLA) Snapshot
|
Open
A$0.28
|
Previous Close
A$0.29
|
|
|
Day High
A$0.28
|
Day Low
A$0.28
|
|
|
52 Week High
10/29/12 - A$0.47
|
52 Week Low
09/19/12 - A$0.20
|
|
|
Market Cap
24.9M
|
Average Volume 10 Days
52.1K
|
|
|
EPS TTM
A$-0.07
|
Shares Outstanding
87.3M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
viralytics ltd (VLA) Related Businessweek News
No Related Businessweek News Foundviralytics ltd (VLA) Details
Viralytics Limited, a biotechnology company, engages in the development of oncolytic virotherapy for the treatment of a range of cancers principally in Australia. The company primarily develops CAVATAK, an oncolytic virus that lyses cancer cells, which is in a Phase II clinical trial for the treatment of late stage melanoma; has completed a Phase I single dose-escalation intravenous study for the treatment of melanoma, breast, prostate, and colon cancers; and has completed a multi dose intratumoral trial for the treatment of late stage head and neck cancers. It also develops EVATAK drug, which is in a preclinical stage for the treatment of various cancers. The company was formerly known as Psiron Limited and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Pymble, Australia.
Last Reported Date: 08/31/12
viralytics ltd (VLA) Top Compensated Officers
viralytics ltd (VLA) Key Developments
Viralytics Limited advised that Mr. Paul Hopper will cease to act as Executive Chairman on April 30, 2013 following the appointment of Dr. Malcolm McCol as Chief Executive Officer and an effective transition of responsibilities to Dr. McCol. Mr. Hopper will resume his role as Non-Executive Chairman effective May 1, 2013.
Viralytics Limited advised that effective on 27 February 2013, the company's principal administrative office has moved to Suite 305, 66 Hunter St, Sydney NSW 2000.
Viralytics Limited reported earnings results for the six months ended December 31, 2012. For the period, the company reported total income of AUD 720,455 against AUD 129,254 a year ago. Loss from ordinary activities before income tax was AUD 2,511,315 against AUD 2,714,998 a year ago. Comprehensive income was AUD 2,511,315 or 3.3 cents diluted loss per share against AUD 2,714,998 or 4.6 cents diluted loss per share a year ago. Net cash used in operating activities was AUD 1,235,266 and purchase of Plant and equipment was AUD 6,445 against net cash used in operating activities of AUD 1,725,542 and purchase of Plant and equipment of AUD 9,082 a year ago.
| Recently Viewed | |||
| VLA:AU | A$0.28 AUD | -0.005 | |
| Company | Last | Change | |
| No competitor information is available for VLA. | |||
| View Industry Companies | |||
Industry Analysis
VLA
Industry Average
| Valuation | VLA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 2.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact VIRALYTICS LTD, please visit www.viralytics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








